Abiopharma

🔍 Kaplan Andrew Jay (Director)

Company: NextTrip, Inc. (NTRP)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 16,667 shares of Series A Nonvoting Convertible Preferred Stock (Derivative)
  Date: 2026-04-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 16,667.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1, F1, F1, F2
• Acquired 8,333 shares of Warrant at $3.0 per share (Derivative)
  Date: 2026-04-15 | Code: J | Expires: 2031-04-15 | Exercise: 2026-04-15 | equity_swap_involved: 0 | shares_owned_after: 8,333.00 | transaction_form_type: 4 | Footnotes: F4, F1, F2

Footnotes:

• F1: Each share of Series A Nonvoting Convertible Preferred Stock is convertible into one share of Common Stock. The shares are not convertible into Common Stock until shareholder approval is received after which it will automatically convert to common shares on the third business day after such approval is received. There is no expiration date for the Series A Nonvoting Convertible Preferred Stock. The price of each share of Series A Non is $3.00 and includes 1/2 warrant with an initial exercise date which is six months from the issue date and a term of three years.
• F2: The securities are held by KC Global Media Asia LLC ("KCGM"). Mr. Kaplan serves as Chairman of KCGM and is deemed to beneficially own the securities held by KCGM.
• F3: Mr. Kaplan disclaims beneficial ownership of all securities held by KCGM in excess of his pecuniary interest, if any, and this report shall not be deemed an admission that he is the beneficial owner of, or has pecuniary interest in, any such excess shares for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• F4: The shares were purchased pursuant to a Securities Purchase Agreement between the Issuer and the Reporting Person.